I. L. Ray-Coquard

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, C. Sessa, Andreas du Bois et al. · International Journal of Gynecological Cancer · 2019 · 400 citations · Full text

Medicine, Oncology, Pathology +17

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier et al. · The Lancet Oncology · 2020 · 322 citations · Full text

Medicine, Oncology, Pharmacology +10

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

Sant P. Chawla, Jean‐Yves Blay, I. L. Ray-Coquard et al. · Journal of Clinical Oncology · 2011 · 77 citations

Medicine, Oncology, Pharmacology +14

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann et al. · Gynecologic Oncology · 2019 · 64 citations

Medicine, Oncology, Pharmacology +15